Amarin Corporation Announces Encore Presentation of Results of the Apolipoprotein C-iii - Post-Hoc Analysis from Marine and Anchor Studies of Vascepa
Aug 27 15
Amarin Corporation plc announced the encore presentation of findings from a post-hoc analysis examining the effects of icosapent ethyl (VascepaA(R)) on Apolipoprotein C-III (ApoC-III) levels in both very high triglyceride (VHTG) and high triglyceride (HTG) patient populations. The poster titled, "Icosapent Ethyl (eicosapentaenoic acid ethyl ester): Effects on Apolipoprotein C-III in Patients from the MARINE and ANCHOR Studies," will be on display at the European Society of Cardiology 2015 Annual Congress in London, England, Session 302 Poster Session #2. The results will be presented by lead investigator, Dr. Christie Ballantyne, Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center on August 30, 2015. The analysis evaluated the effects of EPA-only prescription Vascepa, alone or in combination with statin therapy, on ApoC-III levels in 148 patients with VHTG levels in the MARINE study of Vascepa and 612 patients with HTG levels in the ANCHOR study of Vascepa. In Marine, Vascepa 4 g/day statistically significantly reduced ApoC-III levels by 25.1% (P (0.0001) versus placebo. In Anchor, Vascepa 4 g/day statistically significantly reduced ApoC-III levels by 19.2% (P (0.0001) versus placebo. The findings, originally presented at the National Lipid Association Annual Scientific Sessions in 2014, show that at both 4g/day and 2g/day compared to placebo, Vascepa, alone or in combination with statin therapy, significantly reduced ApoC-III levels in adult patients in the MARINE and ANCHOR studies, in which Vascepa also significantly lowered TG levels without raising LDL-C. Further study is needed to determine if the effects of Vascepa, including those on ApoC-III, in patients with hypertriglyceridemia would have clinically meaningful benefit in the human body. About Vascepaa(R) (icosapent ethyl) capsules VASCEPAA(R) (icosapent ethyl) capsules, known in scientific literature as AMR101, is a highly pure-EPA omega-3 prescription product in a 1 gram capsule. VASCEPA (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (a0/00500 mg/dL) hypertriglyceridemia. The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.
Amarin Corporation plc Promotes Joseph T. Kennedy to Executive Vice President, General Counsel and Strategic Initiatives
Aug 11 15
Amarin Corporation plc announced the promotion of Joseph T. Kennedy to Executive Vice President, General Counsel and Strategic Initiatives. With more than 20 years of industry experience, Mr. Kennedy has contributed significantly to progress at the company since joining the company in December 2011 as Senior Vice President, General Counsel. He also played an important role supporting Amarin business development in the establishment of Amarin's U.S. Vascepa co-promotion agreement with Kowa Pharmaceutical America Inc. and collaboration agreement with Eddingpharm in greater China. Mr. Kennedy joined the company with an impressive record of achievement in the life science industry.
Amarin Corporation plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 6 15
Amarin Corporation plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total net revenues of USD 17,707,000 compared to USD 12,606,000 a year ago. Operating loss was USD 26,737,000 compared to USD 25,240,000 a year ago. Loss from operations before taxes was USD 32,049,000 compared to income from operations before taxes of USD 15,734,000 a year ago. Net loss was USD 31,512,000 compared to net income of USD 15,323,000 a year ago. Net loss applicable to common shareholders was USD 62,853,000 or USD 0.35 basic and diluted per share compared to net income applicable to common shareholders of USD 15,323,000 or USD 0.08 per diluted per share a year ago. Non-GAAP Adjusted net loss was USD 27,696,000 or USD 0.15 per basic and diluted share compared to USD 23,433,000 or USD 0.14 per basic and diluted share a year ago.
For the six months, total net revenues were USD 33,640,000 compared to USD 23,573,000 a year ago. Operating loss was USD 53,786,000 compared to USD 50,811,000 a year ago. Loss before income taxes was USD 63,647,000 compared to USD 9,821,000 a year ago. Net loss was USD 62,638,000 compared to USD 10,657,000 a year ago. Net loss applicable to common shareholders was USD 94,847,000 or USD 0.53 basic and diluted per share compared to USD 10,657,000 or USD 0.07 per diluted per share a year ago. Non-GAAP Adjusted net loss was USD 56,253,000 or USD 0.32 per basic and diluted share compared to USD 51,921,000 or USD 0.30 per basic and diluted share a year ago. The company has lowered net cash used in operating activities to USD 37.6 million in the six months ended June 30, 2015 compared to USD 38.8 million in the same period in 2014.